FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma By Ogkologos - July 22, 2026 168 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LITESPARK-022 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Toothbrushes and ctDNA: Exciting early detection concepts from new teams formed... May 11, 2022 FDA Approves Tepotinib for Metastatic Non-Small Cell Lung Cancer February 20, 2024 Clinical Trials in Molecular Testing for Early-Stage Lung Cancer: IMpower010, ADAURA,... June 15, 2022 Autumn and Letting Go September 29, 2021 Load more HOT NEWS Abnormal Results from Prenatal Blood Test Could Point to Cancer in... The American Rescue Act: What You Need to Know Visits to Online Breast Cancer Communities Could Help Policy Makers and... Detection of ctDNA fractions with a single tumour-informed and tumour-agnostic profiling...
